Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Fosfomycin (calcium)

Fosfomycin (MK-0955) calcium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin calcium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[1][2].

Product Specifications

CAS Number

[26016-98-8]

Product Name Alternative

MK-​0955 (calcium)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Fosfomycin-calcium.html

Purity

98.0

Solubility

H2O : 50 mg/mL (ultrasonic; adjust pH to 2 with HCl)

Smiles

C[C@H]1[C@@H](P([O-])([O-])=O)O1.[Ca+2]

Molecular Formula

C3H5CaO4P

Molecular Weight

176.12

Precautions

H302, H315, H319, H335

References & Citations

[1]Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel) . 2017 Oct 31;6 (4) . pii: E24.|[2]Falagas ME, et al. Fosfomycin. Clin Microbiol Rev. 2016 Apr. 29 (2) :321-47.|[3]Inouye S, et al. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn. 1982 Sep. 5 (9) :659-69.|[4]Inouye S, et al. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn. 1982 Dec. 5 (12) :941-50.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Front Cell Infect Microbiol. 2019 Jul 15:9:253.|J Med Microbiol. 2019 Mar;68 (3) :493-502.|ACS Infect Dis. 2024 Aug 9;10 (8) :2961-2977.|Antibiotics (Basel) . 2021 Sep 14;10 (9) :1110.|bioRxiv. 2024 May 10.|bioRxiv. 2025 January 19.|J Antibiot (Tokyo) . 2025 Mar;78 (4) :265-273.|MedComm (2020) . 2025 Jan 8;6 (1) :e70046.|Molecules. 2025 Mar 9;30 (6) :1224.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Infect Genet Evol. 2025 Sep:133:105780.|Microb Pathog. 2025 Oct 25.|Microbiol Spectr. 2025 Sep 2;13 (9) :e0152125.
Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)
MBS1014145-01 0.02 mg (E-Coli)

Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)

Ask
View Details
Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)
MBS1014145-02 0.02 mg (Yeast)

Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)

Ask
View Details
Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)
MBS1014145-03 0.1 mg (E-Coli)

Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)

Ask
View Details
Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)
MBS1014145-04 0.1 mg (Yeast)

Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)

Ask
View Details
Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)
MBS1014145-05 0.02 mg (Baculovirus)

Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)

Ask
View Details
Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)
MBS1014145-06 0.02 mg (Mammalian-Cell)

Recombinant Cyanothece sp. Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD)

Ask
View Details